RxDoctor Payments Data

Nancy Dantzler

Family · Altus, OKNPI 1598779266

Payments from drug & device makers

$1,483in general payments, 2019–2025

Across 85 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$445
  • AstraZeneca$269
  • Pfizer$137
  • Boehringer Ingelheim$108
  • GSK$107
  • AbbVie$87
  • plus $331 from 12 others

What the payments were for

  • Food & beverage$1,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,483 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$66,829
Medicare patients
273
Services billed
3,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide45$49,831
MounjaroTirzepatide39$46,952
OzempicSemaglutide38$38,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$37,348
JardianceEmpagliflozin30$32,655
EliquisApixaban39$31,758
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$29,048
VraylarCariprazine Hcl17$23,784
FarxigaDapagliflozin Propanediol18$21,487
TradjentaLinagliptin17$15,093
JanuviaSitagliptin Phosphate15$10,688
LinzessLinaclotide13$7,600
MyrbetriqMirabegron12$5,658
Novolog FlexpenInsulin Aspart14$3,691
Albuterol Sulfate HfaAlbuterol Sulfate117$2,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$445$96,78384 claims
Boehringer IngelheimJardiance, Tradjenta$108$47,74847 claims
GSKTrelegy Ellipta$107$37,34854 claims
PfizerEliquis$137$31,75839 claims
AbbVieVraylar, Linzess$87$31,38430 claims
AstraZenecaFarxiga, Symbicort$269$24,29030 claims
MerckJanuvia$17$10,68815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Altus

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →